# External AI Blocked: Phoenix V3 Spatial Active-P0 Closure

Status: external review blocked, not a review verdict.

This records the failed attempt to obtain an external Gemini review for:

```text
docs/reviews/call_for_review_phoenix_v3_spatial_active_p0_closure_2026-06-21.md
```

Requested output path:

```text
docs/reviews/gemini_phoenix_v3_spatial_active_p0_closure_review_2026-06-21.md
```

Error output path:

```text
docs/reviews/gemini_phoenix_v3_spatial_active_p0_closure_review_2026-06-21.stderr.txt
```

The Gemini CLI did not produce an external review verdict. The stderr records:

```text
IneligibleTierError: This client is no longer supported for Gemini Code Assist for individuals.
```

Therefore:

- no `close-active-p0`, `keep-active-p0`, or `reject-current-record` external
  verdict exists;
- no 2-AI consensus exists for closing Spatial as a Phoenix V3 active P0 item;
- `spatial_rayjoin_topology_stream_author_gap` must remain open unless a later
  real external review or user decision explicitly changes that state;
- this blocked record cannot be used as release authorization, M7 promotion, or
  public wording approval.

## Goal-Level Decision Self-Audit

Decision: record the failed Gemini external review attempt without treating it as
2-AI closure evidence.

1. Was I foolish?

   No. The review attempt was appropriate, and recording the failure prevents a
   later agent from mistaking a CLI error for a verdict.

2. If yes, what actions made the decision foolish?

   The foolish action would be to use the failed Gemini run as if it were a
   reviewer decision, or to close Spatial active P0 without an external verdict.

3. Was there another path?

   Yes. I could have skipped external review and made a Codex-only closure
   decision. That would be faster but would violate the user's 2-AI rule for
   goal-level decisions.

4. Can I now try a different path that actually solves the problem?

   Yes. Keep Spatial open, add a machine-readable closure gate that remains
   pending external review, and continue only with evidence-backed generic work
   or a future authenticated review channel.
